Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07172347

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-Segmental Vitiligo

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

The Peking University People's Hospital

Beijing, Beijng, China

Location status: Recruiting

Location contact

Jianzhong Zhang

CONTACT

[email protected]

010-88325471

Jianzhong Zhang

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
  • The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.

Exclusion criteria

  • Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
  • All hair in the vitiligo area on the face is white.
  • Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.
  • Subjects who have previously received depigmentation treatment.
  • Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.

Treatment and study plan

VC005 tablets

Drug

VC005 groups repeat administration for 52 weeks

VC005 Tablets Placebo

Drug

VC005 Placebo groups repeat administration for 52 weeks

Primary outcomes

  1. Percentage change in facial vitiligo area score index (F-VASI) relative to baseline at week 24

    Time frame: Week 24

Study contacts

Contact information is provided by the study sponsor or research team.

xiaojuan lai

CONTACT

[email protected]

15358160458

Sponsors and collaborators

Lead sponsor

Jiangsu vcare pharmaceutical technology co., LTD

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Sep 15, 2025
Registry last updated
Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.